Abiopharma

🔍 OConnell Daniel Joseph (Director)

Company: Acumen Pharmaceuticals, Inc. (ABOS)

Report Date: 2026-01-08

Detailed Transactions and Holdings:

• Sold 8,143 shares of Common Stock at $1.8194 per share (Direct)
  Date: 2026-01-08 | Code: S | equity_swap_involved: 0 | shares_owned_after: 611,839.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 12,941 shares of Common Stock at $1.7643 per share (Direct)
  Date: 2026-01-09 | Code: S | equity_swap_involved: 0 | shares_owned_after: 598,898.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 5,388 shares of Common Stock at $1.7273 per share (Direct)
  Date: 2026-01-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 593,510.00 | transaction_form_type: 4 | Footnotes: F1, F4

Footnotes:

• F1: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 27, 2025.
• F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7200 to $1.8700. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7100 to $1.8100. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.6700 to $1.8400. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.